Loading...
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan, M Neven, P Giobbie-Hurder, A Goldhirsch, A Ejlertsen, B Mauriac, L Forbes, J Smith, I Láng, I Wardley, Andrew M
Regan, M
Neven, P
Giobbie-Hurder, A
Goldhirsch, A
Ejlertsen, B
Mauriac, L
Forbes, J
Smith, I
Láng, I
Wardley, Andrew M
Citations
Altmetric:
Abstract
Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.
Description
Date
2011-11
Publisher
Collections
Keywords
Type
Article
Citation
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. 2011, 12 (12):1101-8 Lancet Oncol